We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp Aims to Prioritize Inpatient Coronavirus Testing
Read MoreHide Full Article
Laboratory Corporation of America Holdings (LH - Free Report) , or LabCorp, announced plans to explore all possible options to prioritize coronavirus testing for the hospital inpatient population. Notably, such a population includes patients, who are currently being treated for suspected coronavirus infection.
Currently, the company is on track to finalize options throughout the week and will subsequently work with hospitals for the implementation of the same.
With the recent strides, LabCorp aims to strengthen its LabCorp Diagnostics (LCD) segment globally.
Significance of the Announcement
Per the company, it has been continuing to add testing capacity per the guidelines of the Centers for Disease Control and Prevention (“CDC”) and other health authorities to meet the growing demands. LabCorp is also on track to advise healthcare providers to follow the guidance to prioritize testing for patients, who are currently hospitalized and undergoing treatments for suspected coronavirus infection.
Notably, the company is planning to provide technical support to hospitals that it serves to perform on-site serological and molecular tests for coronavirus, including Cepheid’s recently announced Xpert Xpress SARS-CoV-2 molecular test, once available.
LabCorp is continuously coordinating with manufacturers that are developing additional test options. The company will also continue to work closely with healthcare providers to teach them how to use the tests once those become available.
Industry Prospects
Per a report by MarketsAndMarkets, the global in-vitro diagnostics market will grow from $87.93 billion in 2018 to $68.12 billion by 2023, witnessing a CAGR of 5.2% during the period. Factors like the growing incidences of chronic and infectious diseases, increasing adoption of fully automated instruments, automation in laboratories, and increasing adoption of point-of-care testing are likely to drive the market.
The global outbreak of coronavirus is expected to extend the scope of the market in the months to come.
Recent Developments in LCD Segment
Of late, the LCD segment has been making a lot of efforts to contain the coronavirus outbreak.
In March, the company announced that it reached the capability of performing more than 20,000 coronavirus tests per day, representing a significant increase in its capacity since the release. It is now performing tests in three of its largest labs in the country.
Apart from making efforts to contain the pandemic, LabCorp is serving the vulnerable patients, who do not have the coronavirus. In March, it announced that it is dedicating the first hour of service each day at its nearly 2,000 patient service centers across the United States for the non-coronavirus testing needs of other patients. The company intends to make it easier for patients, who are at higher risk and need critical lab testing services.
Price Performance
Shares of the company have moved down 26.8% in the past year compared with the industry’s 31.8% decline.
Zacks Rank & Key Picks
Currently, LabCorp carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report) and Hill-Rom Holdings, Inc. .
Medtronic’s long-term earnings growth rate is estimated at 7.1%. The company presently has a Zacks Rank #2.
Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank #2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
LabCorp Aims to Prioritize Inpatient Coronavirus Testing
Laboratory Corporation of America Holdings (LH - Free Report) , or LabCorp, announced plans to explore all possible options to prioritize coronavirus testing for the hospital inpatient population. Notably, such a population includes patients, who are currently being treated for suspected coronavirus infection.
Currently, the company is on track to finalize options throughout the week and will subsequently work with hospitals for the implementation of the same.
With the recent strides, LabCorp aims to strengthen its LabCorp Diagnostics (LCD) segment globally.
Significance of the Announcement
Per the company, it has been continuing to add testing capacity per the guidelines of the Centers for Disease Control and Prevention (“CDC”) and other health authorities to meet the growing demands. LabCorp is also on track to advise healthcare providers to follow the guidance to prioritize testing for patients, who are currently hospitalized and undergoing treatments for suspected coronavirus infection.
Notably, the company is planning to provide technical support to hospitals that it serves to perform on-site serological and molecular tests for coronavirus, including Cepheid’s recently announced Xpert Xpress SARS-CoV-2 molecular test, once available.
LabCorp is continuously coordinating with manufacturers that are developing additional test options. The company will also continue to work closely with healthcare providers to teach them how to use the tests once those become available.
Industry Prospects
Per a report by MarketsAndMarkets, the global in-vitro diagnostics market will grow from $87.93 billion in 2018 to $68.12 billion by 2023, witnessing a CAGR of 5.2% during the period. Factors like the growing incidences of chronic and infectious diseases, increasing adoption of fully automated instruments, automation in laboratories, and increasing adoption of point-of-care testing are likely to drive the market.
The global outbreak of coronavirus is expected to extend the scope of the market in the months to come.
Recent Developments in LCD Segment
Of late, the LCD segment has been making a lot of efforts to contain the coronavirus outbreak.
In March, the company announced that it reached the capability of performing more than 20,000 coronavirus tests per day, representing a significant increase in its capacity since the release. It is now performing tests in three of its largest labs in the country.
Apart from making efforts to contain the pandemic, LabCorp is serving the vulnerable patients, who do not have the coronavirus. In March, it announced that it is dedicating the first hour of service each day at its nearly 2,000 patient service centers across the United States for the non-coronavirus testing needs of other patients. The company intends to make it easier for patients, who are at higher risk and need critical lab testing services.
Price Performance
Shares of the company have moved down 26.8% in the past year compared with the industry’s 31.8% decline.
Zacks Rank & Key Picks
Currently, LabCorp carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report) and Hill-Rom Holdings, Inc. .
ResMed has a projected long-term earnings growth rate of 14.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is estimated at 7.1%. The company presently has a Zacks Rank #2.
Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank #2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>